GlassScriptPhysician profile
Vasantha Peraje Pai
NPI 1306921218
$20,518.80
in general payments reported to CMS, 2019-2025
44 companies · $2,931 in 2025
The $2,931 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,984 · 2020: $1,880 · 2021: $2,473 · 2022: $4,173 · 2023: $2,982 · 2024: $4,096 · 2025: $2,931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,714 · Debt Forgiveness: $1,154 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,714.38 |
| Debt Forgiveness | $1,154.14 |
| Education | $140.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,676.51 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,037.64 | 2019-2025 | Xifaxan, Trulance |
| Olympus America INC. | $3,034.78 | 2022-2024 | |
| Gilead Sciences, INC. | $1,171.54 | 2019-2025 | |
| Pfizer INC. | $1,165.00 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,153.09 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $932.08 | 2020-2025 | Stelara, Tremfya |
| Intercept Pharmaceuticals, INC. | $715.46 | 2020-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $659.55 | 2019-2024 | Linzess |
| Qol Medical, LLC | $536.48 | 2019-2025 | Sucraid, Sucraid |
| Redhill Biopharma INC. | $508.54 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Ardelyx, INC. | $366.58 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $348.99 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $272.09 | 2022-2025 | Dupixent |
| Celgene Corporation | $256.06 | 2021-2024 | Zeposia |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $205.88 | 2021-2024 | Dificid, Zinplava |
| Daiichi Sankyo INC. | $145.83 | 2019-2020 | |
| Lilly USA, LLC | $127.80 | 2024 | Omvoh |
| Madrigal Pharmaceuticals | $118.09 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $112.26 | 2021-2023 | |
| Braintree Laboratories, INC. | $111.31 | 2019-2022 | |
| Alfasigma USA, INC. | $99.63 | 2020-2022 | |
| Vivus LLC | $81.08 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $80.53 | 2024-2025 | Zenpep |
| Allergan, INC. | $75.92 | 2019-2020 | |
| Amgen INC. | $72.63 | 2023 | Amjevita, Avsola |
| Phathom Pharmaceuticals, INC. | $62.10 | 2025 | Voquezna |
| Capsovision, INC. | $50.42 | 2023-2025 | Capsocam Plus |
| Ferring Pharmaceuticals INC. | $38.93 | 2020-2023 | Rebyota |
| Alnylam Pharmaceuticals INC. | $36.00 | 2022-2023 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.19 | 2024 | Cyltezo |
| Celltrion USA INC. | $31.12 | 2023 | Yuflyma |
| Echosens North America, INC. | $27.48 | 2024 | Fibroscan |
| Evoke Pharma, INC. | $21.63 | 2021 | |
| Boston Scientific Corporation | $21.43 | 2024 | Speedband Superview Super 7 |
| Concordia Pharmaceuticals INC. | $20.36 | 2019 | |
| Ethicon US, LLC | $18.22 | 2022 | |
| Shire North American Group INC | $17.31 | 2019 | |
| Eisai INC. | $14.25 | 2021 | |
| Merit Medical Systems INC | $13.51 | 2023 | Big60 Inflation Device, Elation Balloon Dilator, Endomaxx Stent and Delivery System |
| Fresenius Kabi USA, LLC | $13.35 | 2023 | Idacio |
| Conmed Corporation | $12.54 | 2020 | |
| Dova Pharmaceuticals | $11.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasantha Pai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.